Keyword Index
Browse for an article via relevant keywords across our entire electronic archive
Search results for: G
Results 71 - 80 of 306 shown below
-
Mutation and deletion analysis of GFR
-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumoursdoi:10.1038/sj.bjc.6690367
GDNFR
Mutation and deletion analysis of GFR
-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumoursdoi:10.1038/sj.bjc.6690367
-
Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene
doi:10.1038/sj.bjc.6601064
-
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
doi:10.1038/sj.bjc.6601504
-
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors
doi:10.1038/sj.bjc.6601550
-
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
advance online publication, 2004-04-06 00:00:00.000;
doi:10.1038/sj.bjc.6601768
-
Targeting the epidermal growth factor receptor
advance online publication, 2004-07-06 00:00:00.000;
doi:10.1038/sj.bjc.6601921
-
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells
advance online publication, 2004-11-16 00:00:00.000;
doi:10.1038/sj.bjc.6602231
-
Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro
advance online publication, 2004-11-16 00:00:00.000;
doi:10.1038/sj.bjc.6602242
-
CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy
advance online publication, 2004-12-14 00:00:00.000;
doi:10.1038/sj.bjc.6602296
-
Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines
advance online publication, 2005-03-22 00:00:00.000;
doi:10.1038/sj.bjc.6602461
-
Selective inhibition of TNF-
-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinibadvance online publication, 2005-04-19 00:00:00.000;
doi:10.1038/sj.bjc.6602548
-
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
doi:10.1038/sj.bjc.6602559
-
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
advance online publication, 2005-05-03 00:00:00.000;
doi:10.1038/sj.bjc.6602569
-
Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients
advance online publication, 2005-06-07 00:00:00.000;
doi:10.1038/sj.bjc.6602652
-
Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
advance online publication, 2005-09-27 00:00:00.000;
doi:10.1038/sj.bjc.6602793
-
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
advance online publication, 2005-11-15 00:00:00.000;
doi:10.1038/sj.bjc.6602865
-
Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
advance online publication, 2005-11-22 00:00:00.000;
doi:10.1038/sj.bjc.6602875
-
Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
advance online publication, 2006-02-21 00:00:00.000;
doi:10.1038/sj.bjc.6602999
-
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
advance online publication, 2006-05-02 00:00:00.000;
doi:10.1038/sj.bjc.6603159
-
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells
advance online publication, 2006-07-04 00:00:00.000;
doi:10.1038/sj.bjc.6603237
-
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
advance online publication, 2006-08-29 00:00:00.000;
doi:10.1038/sj.bjc.6603308
-
Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity
advance online publication, 2007-01-09 00:00:00.000;
doi:10.1038/sj.bjc.6603544
-
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
advance online publication, 2007-02-20 00:00:00.000;
doi:10.1038/sj.bjc.6603620
-
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
advance online publication, 2007-02-27 00:00:00.000;
doi:10.1038/sj.bjc.6603665
-
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
advance online publication, 2007-03-13 00:00:00.000;
doi:10.1038/sj.bjc.6603669
-
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
advance online publication, 2007-03-27 00:00:00.000;
doi:10.1038/sj.bjc.6603710
-
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts
advance online publication, 2007-06-26 00:00:00.000;
doi:10.1038/sj.bjc.6603791
-
Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice
advance online publication, 2007-05-29 00:00:00.000;
doi:10.1038/sj.bjc.6603828
-
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
doi:10.1038/sj.bjc.6603949
-
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
advance online publication, 2007-11-13 00:00:00.000;
doi:10.1038/sj.bjc.6604068
-
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
advance online publication, 2007-12-04 00:00:00.000;
doi:10.1038/sj.bjc.6604121
-
A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)
advance online publication, 2008-02-05 00:00:00.000;
doi:10.1038/sj.bjc.6604232
-
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
advance online publication, 2008-02-19 00:00:00.000;
doi:10.1038/sj.bjc.6604249
-
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
advance online publication, 2009-03-10 00:00:00.000;
doi:10.1038/sj.bjc.6604980
-
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib
doi:10.1038/sj.bjc.6602062
-
Interstitial lung disease associated with drug therapy
doi:10.1038/sj.bjc.6602063
-
Understanding the mechanisms of drug-associated interstitial lung disease
doi:10.1038/sj.bjc.6602065
-
Extensive experience of disease control with gefitinib and the role of prognostic markers
doi:10.1038/sj.bjc.6601476
-
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice
doi:10.1038/sj.bjc.6601477
-
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib
doi:10.1038/sj.bjc.6601478
-
Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
doi:10.1038/sj.bjc.6601479
-
Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer
doi:10.1038/sj.bjc.6600366
-
Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas
doi:10.1038/sj.bjc.6690417
-
Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: Levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue
doi:10.1054/bjoc.2000.1712
-
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
doi:10.1038/sj.bjc.6601238
-
Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer
doi:10.1038/sj.bjc.6600366
